1. Home
  2. AMPX vs PHVS Comparison

AMPX vs PHVS Comparison

Compare AMPX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amprius Technologies Inc.

AMPX

Amprius Technologies Inc.

HOLD

Current Price

$7.84

Market Cap

1.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPX
PHVS
Founded
2008
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AMPX
PHVS
Price
$7.84
$26.03
Analyst Decision
Strong Buy
Buy
Analyst Count
7
9
Target Price
$13.33
$39.44
AVG Volume (30 Days)
5.4M
475.7K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,408,000.00
N/A
Revenue This Year
$205.06
N/A
Revenue Next Year
$127.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
234.14
N/A
52 Week Low
$1.70
$11.51
52 Week High
$16.03
$29.80

Technical Indicators

Market Signals
Indicator
AMPX
PHVS
Relative Strength Index (RSI) 31.59 53.90
Support Level $8.77 $25.27
Resistance Level $11.58 $26.09
Average True Range (ATR) 0.69 1.20
MACD -0.23 0.04
Stochastic Oscillator 1.46 66.98

Price Performance

Historical Comparison
AMPX
PHVS

About AMPX Amprius Technologies Inc.

Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: